Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 195

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2

Open access
El-Shennawy, Lamiaa, Hoffmann, Andrew D., Dashzeveg, Nurmaa Khund, McAndrews, Kathleen M., Mehl, Paul J., Cornish, Daphne, Yu, Zihao, Tokars, Valerie L., Nicolaescu, Vlad, Tomatsidou, Anastasia, Mao, Chengsheng, Felicelli, Christopher J., Tsai, Chia-Feng, Ostiguin, Carolina, Jia, Yuzhi, Li, Lin, Furlong, Kevin, Wysocki, Jan, Luo, Xin, Ruivo, Carolina F., Batlle, Daniel, Hope, Thomas J., Shen, Yang, Chae, Young Kwang, Zhang, Hui, LeBleu, Valerie S., Shi, Tujin, Swaminathan, Suchitra, Luo, Yuan, Missiakas, Dominique, Randall, Glenn C., Demonbreun, Alexis R., Ison, Michael G., Kalluri, Raghu, Fang, Deyu, Liu, Huiping · 2022 · Nature Communications

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the pandemic of the coronavirus induced disease 2019 (COVID-19) with evolving variants of concern. It remains urgent to identify novel approaches against broad strains of SARS-CoV-2, which infect host cells via the entry receptor angiotensin-converting enzyme 2 (ACE2). Herein, we report an increase in circulating extracellular vesicles (EVs) that express ACE2 (evACE2) in plasma of COVID-19 patients, which levels are associated with severe pathogenesis. Importantly, evACE2 isolated from human plasma or cells neutralizes SARS-CoV-2 infection by competing with cellular ACE2. Compared to vesicle-free recombinant human ACE2 (rhACE2), evACE2 shows a 135-fold higher potency in blocking the binding of the viral spike protein RBD, and a 60- to 80-fold higher efficacy in preventing infections by both pseudotyped and authentic SARS-CoV-2. Consistently, evACE2 protects the hACE2 transgenic mice from SARS-CoV-2-induced lung injury and mortality. Furthermore, evACE2 inhibits the infection of SARS-CoV-2 variants (α, β, and δ) with equal or higher potency than for the wildtype strain, supporting a broad-spectrum antiviral mechanism of evACE2 for therapeutic development to block the infection of existing and future coronaviruses that use the ACE2 receptor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-27893-2

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 195

Metadata

Authors
El-Shennawy, L., Hoffmann, A. D., Dashzeveg, N. K., McAndrews, K. M., Mehl, P. J., Cornish, D., Yu, Z., Tokars, V. L., Nicolaescu, V., Tomatsidou, A., Mao, C., Felicelli, C. J., Tsai, C.-F., Ostiguin, C., Jia, Y., Li, L., Furlong, K., Wysocki, J., Luo, X., Ruivo, C. F., Batlle, D., Hope, T. J., Shen, Y., Chae, Y. K., Zhang, H., LeBleu, V. S., Shi, T., Swaminathan, S., Luo, Y., Missiakas, D., Randall, G. C., Demonbreun, A. R., Ison, M. G., Kalluri, R., Fang, D., & Liu, H.
Venue
Nature Communications
Published
2022-01-20
Volume
13
Issue
1
Pages
405-405
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4206103017
Cited by
195
References
25
FWCI
18.94
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. https://app.cochat.ai/papers/10.1038/s41467-021-27893-2
The paper
El-Shennawy, L., Hoffmann, A. D., Dashzeveg, N. K., McAndrews, K. M., Mehl, P. J., Cornish, D., Yu, Z., Tokars, V. L., Nicolaescu, V., Tomatsidou, A., Mao, C., Felicelli, C. J., Tsai, C.-F., Ostiguin, C., Jia, Y., Li, L., Furlong, K., Wysocki, J., Luo, X., . . . Liu, H. (2022). Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nature Communications. https://doi.org/10.1038/s41467-021-27893-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.